PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-7.97
Negative P/E while Healthcare median is -4.24. Seth Klarman would scrutinize path to profitability versus peers.
601.61
P/S exceeding 1.5x Healthcare median of 13.80. Jim Chanos would check for potential multiple compression risks.
1.99
P/B 50-90% of Healthcare median of 3.63. Mohnish Pabrai would examine if this discount presents opportunity.
-34.45
Negative FCF while Healthcare median P/FCF is -19.47. Seth Klarman would investigate cash flow improvement potential.
-34.91
Negative operating cash flow while Healthcare median P/OCF is -15.83. Seth Klarman would investigate operational improvement potential.
1.99
Fair value ratio 50-90% of Healthcare median of 3.63. Mohnish Pabrai would examine if this gap presents opportunity.
-3.14%
Negative earnings while Healthcare median yield is -0.75%. Seth Klarman would investigate path to profitability.
-2.90%
Negative FCF while Healthcare median yield is -0.65%. Seth Klarman would investigate cash flow improvement potential.